Additionally, although the prescription rate was not high in our study cohort, glucagon-like peptide 1-receptor agonist or sodium glucose cotransporter 2-inhibitor can reduce weight during long-term use among diabetic agents, so it could be considered when interpretating higher depression risk in low BMI patients at baseline. Here, SLC5A2 is linked to major depressive disorder.